Evidence map›Paper›PMID 33267610›Full record

Trial reportCirculation2021

Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.

Bernard R Chaitman, Karen P Alexander, Derek D Cyr, Jeffrey S Berger, Harmony R Reynolds, Sripal Bangalore, William E Boden, Renato D Lopes, Marcin Demkow, Gian Piero Perna and 14 more

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01471522 nacompletednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

TypeinterventionalSponsorNYU Langone HealthRan2012 to 2023Enrolled5,179ConditionsCardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart DiseasesArmscardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
NCT07577518 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Percutaneous Intervention Versus Optimal Medical Therapy in Chronic Coronary Syndrome (PIVOT) Trial

TypeinterventionalSponsorSeoul National University HospitalRan2026 to 2034Enrolled2,301ConditionsChronic Coronary SyndromeArmspercutaneous coronary intervention, Guideline-directed Optimal Medical treatment, Carvedilol Sustained-Release (SR) (Nested RCT subset), Carvedilol Immediate-Release (IR) (Nested RCT subset)
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Outcomes by sex in the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Guideline for Chronic Coronary Syndrome - 2025.Arquivos brasileiros de cardiologia · 2025
    Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 8 countries.

Bernard R ChaitmanSaint Louis University School of Medicine, MO (B.R.C.).
Karen P AlexanderDuke Clinical Research Institute, Durham, NC (K.P.A., D.D.C., R.D.L., S.M.O., F.W.R.).
Derek D CyrDuke Clinical Research Institute, Durham, NC (K.P.A., D.D.C., R.D.L., S.M.O., F.W.R.).
Jeffrey S BergerNew York University Grossman School of Medicine, New York (J.S.B., H.R.R., S.B., J.S.H.).
Harmony R ReynoldsNew York University Grossman School of Medicine, New York (J.S.B., H.R.R., S.B., J.S.H.).
Sripal BangaloreNew York University Grossman School of Medicine, New York (J.S.B., H.R.R., S.B., J.S.H.).
William E BodenVA New England Healthcare System, Boston, MA (W.E.B.).
Renato D LopesDuke Clinical Research Institute, Durham, NC (K.P.A., D.D.C., R.D.L., S.M.O., F.W.R.).
Marcin DemkowInstitute of Cardiology, Warsaw, Poland (M.D.).
Gian Piero PernaOspedali Riuniti of Ancona, Italy (G.P.P.).
Robert K RiezebosHeartcentre OLVG, Amsterdam, The Netherlands (R.K.R.).
Edward O McFallsMinneapolis V.A. Medical Center, MN (E.O.M.).
Subhash BanerjeeVeterans Affairs North Texas Health Care System, Dallas (S.B.).
Akshay BagaiTerrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, ON, Canada (A.B.).
Gilbert GosselinMontreal Heart Institute, QC, Canada (G.G.).
Sean M O'BrienDuke Clinical Research Institute, Durham, NC (K.P.A., D.D.C., R.D.L., S.M.O., F.W.R.).
Frank W RockholdDuke Clinical Research Institute, Durham, NC (K.P.A., D.D.C., R.D.L., S.M.O., F.W.R.).
David D WatersUniversity of California, San Francisco (D.D.W.).
Kristian A ThygesenAarhus University Hospital, Denmark (K.A.T.).
Gregg W StoneThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and the Cardiovascular Research Foundation, New York, NY (G.W.S.).
Harvey D WhiteGreen Lane Cardiovascular Services, Auckland City Hospital, and University of Auckland, New Zealand (H.D.W.).
David J MaronDepartment of Medicine, Stanford University School of Medicine, CA (D.J.M.).
Judith S HochmanNew York University Grossman School of Medicine, New York (J.S.B., H.R.R., S.B., J.S.H.).
ISCHEMIA Research Group
Clinical Research Institute · USNew York University · USAarhus University Hospital · DKAuckland City Hospital · NZCardiovascular Institute of the South · USInstitute of Cardiology · PLMinneapolis VA Medical Center · USMontreal Heart Institute · CAOLVG · NLOspedali Riuniti di Ancona · ITSaint Louis University · USStanford University · USSt Michael's Hospital · GBTwitter (United States) · USUniversity of California, San Francisco · USVA Boston Healthcare System · USVA North Texas Health Care System · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
BARI II GRANT PROPOSAL FOR ECG CORE LABORATORYU01HL061746 · NHLBI · SAINT LOUIS UNIVERSITY · PI CHAITMAN, BERNARD R · 2000 to 2008
$1.6M
NCATS NIH HHS UL1 TR001445NCATS NIH HHS UL1 TR002243NHLBI NIH HHS U01 HL061746NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

backgroundIn the ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches), an initial invasive strategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparison with a conservative strategy in patients with stable ischemic heart disease and moderate/severe myocardial ischemia. The most frequent component of composite cardiovascular end points was myocardial infarction (MI).

methodsISCHEMIA prespecified that the primary and major secondary composite end points of the trial be analyzed using 2 MI definitions. For procedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas the secondary definition used cardiac troponin. Procedural thresholds were >5 times the upper reference level for percutaneous coronary intervention and >10 times for coronary artery bypass grafting. Procedural MI definitions included (1) a category of elevated biomarker only events with much higher biomarker thresholds, (2) new ST-segment depression of ≥1 mm for the primary and ≥0.5 mm for the secondary definition, and (3) new coronary dissections

resultsProcedural MIs accounted for 20.1% of all MI events with the primary definition and 40.6% of all MI events with the secondary definition. Four-year MI rates in patients undergoing revascularization were more frequent with the invasive versus conservative strategy using the primary (2.7% versus 1.1%; adjusted hazard ratio [HR], 2.98 [95% CI, 1.87-4.73]) and secondary (8.2% versus 2.0%; adjusted HR, 5.04 [95% CI, 3.64-6.97]) MI definitions. Type 1 MIs were less frequent with the invasive versus conservative strategy using the primary (3.40% versus 6.89%; adjusted HR, 0.53 [95% CI, 0.41-0.69];

conclusionsIn ISCHEMIA, type 1 MI events using the primary and secondary definitions during 5-year follow-up were more frequent with an initial conservative strategy and associated with subsequent cardiovascular death. Procedural MI rates were greater in the invasive strategy and with the use of the secondary MI definition. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.

Indexed as

AgedAged, 80 and overCoronary Artery BypassCreatine Kinase, MB FormFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaPercutaneous Coronary InterventionPrognosisProportional Hazards ModelsRisk FactorsCreatine Kinase, MB Formcatheterizationdrug therapymyocardial infarctionmyocardial ischemiamyocardial revascularization

Identifiers

PMID33267610
PMCPMC7902479
OpenAlexW3107022135

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.